The role of Skp2 in extranodal NK/T-cell lymphoma

Chinese Journal of Cancer

Volumn 29, Issue 5, 2010, Pages 567-571

  Guo, Hong Qiang ^a   Pu, Xing Xiang ^a   Guo, Cheng Cheng ^a   Rao, Hui Lan ^a   Li, Hao Ran ^a   Lin, Tong Yu ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

CR rate; Extranodal NK T cell lymphoma; Prognosis; Skp2

Indexed keywords

LACTATE DEHYDROGENASE; S PHASE KINASE ASSOCIATED PROTEIN 2;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIVARIATE ANALYSIS; NK T CELL LYMPHOMA; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 79551577392     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.009.10645     Document Type: Article

References (48)

1. Kim TM, Park YH, Lee SY, et al. Local tumor invasiveness is more predictive of survival than international prognostic index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type [J]. Blood, 2005, 106(12): 3785-3790.
2. Yong W, Zheng W, Zhang Y, et al. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma [J]. Int J Hematol, 2003, 78(2): 163-167.
3. Isobe K, Uno T, Tamaru J, et al. Extranodal natural killer/T-cell lymphoma, nasal type[J]. Cancer, 2006, 106(3): 609-615.
4. Zhang XX, Xie CH, Xu Y, et al. Salvage treatment improved survival of patients with relapsed extranodal natural killer/T-cell lymphoma, nasal type[J]. Int J Radiat Oncol Biol Phys, 2009, 74(3): 747-752
5. Griffin BE. Epstein-Barr virus (EBV) and human disease: facts, opinions and problems[J]. Mutat Res, 2000, 462(2-3): 395-405.
6. Fahraeus R, Fu HL, Ernberg I, et al. Expression of Epstein-Barr virusencoded proteins in nasopharyngeal carcinoma [J]. Int J Cancer, 1988, 42(3): 329-38.
7. Bonnet M, Guinebretiere JM, Kremmer E, et al. Detection of Epstein-Barr virus in invasive breast cancers [J]. J Natl Cancer Inst, 1999, 91(16): 1376-1381.
8. Weiss LM, Movahed LA, Warnke RA, et al. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease [J]. N Engl J Med, 1989, 320(8): 502-506.
9. Kwon JM, Park YH, Kang JH, et al. The effect of Epstein-Barr virus status on clinical outcome in Hodgkin's lymphoma [J]. Ann Hematol, 2006, 85(7): 463-468.
10. Peng M, Lundgren E. Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis [J]. Oncogene, 1992, 7(9): 1775-1782.
11. Brennan P, Floettmann JE, Mehl A, et al. Mechanism of action of a novel latent membrane protein-1 dominant negative [J]. J Biol Chem, 2001, 276(2): 1195-1203.
12. Mosialos G, Birkenbach M, Yalamanchili R, et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family[J]. Cell, 1995, 80(3): 389-99.
13. Gires O, Zimber-Strobl U, Gonnella R, et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule [J]. EMBO J, 1997, 16(20): 6131-6140.
14. Yang X, He Z, Xin B, et al. LMP1 of Epstein-Barr virus suppresses cellular senescence associated with the inhibition of p16INK4a expression [J]. Oncogene, 2000, 19(16): 2002-2013.
15. Cahir McFarland ED, Izumi KM, Mosialos G. Epstein-Barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-kappaB [J]. Oncogene, 1999, 18(49): 6959-6964.
16. Kim JH, Kim WS, Park C. SNARK, a novel downstream molecule of EBV latent membrane protein 1, is associated with resistance to cancer cell death[J]. Leuk Lymphoma, 2008, 49(7): 1392-1398.
17. Masucci MG. Epstein-Barr virus oncogenesis and the ubiquitinproteasome system[J]. Oncogene, 2004, 23(11): 2107-2115.
18. Loda M, Cukor B, Tam SW, et al. Increased proteasome dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas [J]. Nature Med, 1997, 3(2): 231-234.
19. Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 inhibitor protein: prognostic implications in primary breast cancer[J]. Nature Med, 1997, 3(2): 227-230.
20. Tsihlias J, Kapusta LR, DeBoer G, et al. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma [J]. Cancer Res, 1998, 58(3): 542-548.
21. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitinproteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27[J]. Science, 1995, 269(5224): 682-685.
22. Carrano AC, Eytan E, Hershko A, et al. Skp2 is required for ubiquitinmediated degradation of the CDK inhibitor p27 [J]. Nat Cell Biol, 1999, 1(4): 193-199.
23. Sutterluty H, Chatelain E, Marti A, et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells [J]. Nat Cell Biol, 1999, 1(4): 207-214.
24. Tsvetkov LM, Yeh KH, Lee SJ, et al. p27 (Kip1) ubiquitination and degradation is regulated by the SCF-(Skp2) complex through phosphorylated Thr187 in p27[J]. Curr Biol, 1999, 9(12): 661-664.
25. Knight JS, Sharma N, Robertson ES. SCF-Skp2 complex targeted by Epstein-Barr virus essential nuclear antigen[J]. Mol Cell Biol, 2005, 25(5): 1749-1763.
26. Demetrick DJ, Zhang H, Beach D, et al. Chromosomal mapping of the genes for the human CDK2/cyclin A-associated proteins p19 (Skp1A and Skp1B) and p45 (Skp2) [J]. Cytogenet Cell Genet, 1996, 73(1-2): 104-107.
27. Schulman BA, Carrano AC, Jaffrey PD, et al. Lnsights into SCF ubiquin ligases from the structure of the Skp1-Skp2 complex [J]. Nature, 2000, 408(16): 381-386.
28. Dong Y, Sui L, Watanabe Y, et al. S-phase kinase associated protein 2 expression in laryngeal squamous cell carcinomas and its prognostic implications [J]. Oncol Rep, 2003, 10(2): 321-325.
29. Yao HL, Yang ZL, Li YG, et al. Expressions of S-phase kinaseassociated protein 2 and p27 protein in gastric carcinoma and pericancerous tissues [J]. Chinese Journal of Based and Clinics in General Surgery, 2007, 14(3): 308-311. [in Chinese]
30. Li JQ, Wu F, Masaki T, et al. Correlation of Skp2 with carcinogenesis, invasion, metastasis, and prognosis in colorectal tumors [J]. Int J Oncol, 2004, 25(1): 87-95.
31. Radke S, Pirkmaier A, Germain D. Differential expression of the F-box proteins Skp2 and Skp2B in breast cancer [J]. Oncogene, 2005, 24(21): 3448-3458.
32. Shapira M, Ben-Izhak O, Linn S, et al. The prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in colorectal carcinoma [J]. Cancer, 2005, 103(7): 1336-1346.
33. Oliveira AM, Okuno SH, Nascimento AG, et al. Skp2 protein expressionin soft tissue sarcomas[J]. J Clin Oncol, 2003, 21(4): 722-727.
34. Langner C, von Wasielewski R, Ratschek M, et al. Expression of p27 and its ubiquitin ligase subunit Skp2 in upper urinary tract transitional cell carcinoma [J]. Urology, 2004, 64(3): 611-616.
35. Latres E, Chiarle R, Schulman BA, et al. Role of the F-box protein Skp2 in lymphomagenesis [J]. Proc Natl Acad Sci USA, 2001, 98(5): 2515-2520.
36. Signoretti S, Di Marcotullio L, Richardson A, et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer [J]. J Clin Invest, 2002, 110(5): 633-641.
37. Ben-Izhak O, Lahav-Baratz S, Meretyk S, et al. Inverse relationship between Skp2 ubiqitin ligase and the cyclin dependent kinase inhibitor p27Kip in prostate cancer[J]. J Urol, 2003, 170(1): 241-245.
38. Kudo Y, Kitajima S, Sato S, et al. High expression of S-phase kinaseinteracting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas [J]. Cancer Res, 2001, 61(9): 7044-7047.
39. Chiarle R, Fan Y, Piva R, et al. S-phase kinase-associated protein expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase [J]. Am J Pathol, 2002, 160(4): 1457-1466.
40. Chiarle R, Fan Y, Piva R, et al. S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase [J]. Am J Pathol, 2000, 160(4): 1457-1466.
41. Lim MS, Adamsom A, Lin Z, et al. Expression of Skp2 a p27 kip1 ubiquitin ligase in malignant lymphoma: correlation with p27 kip1 and proliferation index[J]. Blood, 2002, 100(8): 2950-2956.
42. Kim SJ, Kim BS, Choi CW, et al. Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract [J]. Leuk Lymphoma, 2006, 47(7): 1265-1273.
43. Xiao J, Yin SM, Xie SF, et al. Relationship between expression of cell regulatory factor SKP2 and drug resistance of HL-60/A cells [J]. Journal of Sun Yat-sen University (Medical Sciences), 2009, 2(30): 137-141. [in Chinese]
44. Wang B, Li XQ, Ma X, et al. Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type [J]. Am J Hematol, 2008, 83(10): 795-799.
45. Uddin S, Hussain A, Ahmed M, et al. S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma [J]. J Pathol, 2008, 216(4): 483-494.
46. Uddin S, Ahmed M, Bavi P, et al. Bortezomib (Velcade1) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer[J]. Cancer Res, 2008, 68(9): 3379-3388.
47. Hussain AR, Ahmed M, Ahmed SO, et al. Proteasome inhibitor MG-132 mediated expression of p27Kip1 via S-phase kinase protein 2 degradation induces cell cycle coupled apoptosis in primary effusion lymphoma cells[J]. Leuk Lymphoma, 2009, 50(7): 1204-1213.
48. Lee J, Suh C, Kang HJ, et al. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma [J]. Ann Oncol, 2008, 19(12): 2079-2083.